Business Context and Reporting Period
This Form 8-K, filed on October 24, 2001, reports E. I. du Pont de Nemours and Company's (DuPont) financial results for the third quarter ended September 30, 2001. The company operates in a challenging global economic environment characterized by a recession in U.S. manufacturing, which has driven significantly lower sales volumes and downward pressure on margins. A major corporate event during the period was the completion of the sale of DuPont Pharmaceuticals to Bristol-Myers Squibb Company on October 1, 2001, for $7.8 billion.
Key Financial Metrics
- Revenue: Consolidated sales for the quarter were $5.64 billion, a 12% decrease from $6.45 billion in the prior year. Segment sales totaled $6.35 billion, down 14%.
- Profitability: Net income was $142 million ($0.13 per share diluted), compared to $562 million ($0.53 per share) in the third quarter of 2000. Underlying earnings (excluding one-time items) were $128 million ($0.12 per share).
- Margins: Segment After-Tax Operating Income (ATOI) excluding one-time items was $284 million, a 61% decline from $725 million in the prior year. EBITDA excluding one-time items was $760 million, down 50%.
- Cash Flow and Liquidity: The filing does not provide specific cash flow statement data or liquidity ratios for the quarter. Management emphasized a focus on "careful cash management."
- Debt: Interest and debt expense was $148 million for the quarter. The filing does not disclose total debt balances.
Material Changes Versus Prior Period
The significant decline in earnings and sales is primarily attributed to the following factors:
- Volume Decline: Worldwide sales volumes decreased by 9%, with U.S. volumes down 12% due to economic weakness. Specific segments like Polyester saw sales drop 28% and Specialty Polymers drop 17%.
- Pricing Pressure: Worldwide local currency selling prices were down 2%. Adverse currency effects, specifically a weaker euro and yen, reduced worldwide segment sales by an additional 2%.
- Costs: While raw material costs moderated (providing a $30 million after-tax benefit versus the prior year), this was insufficient to offset volume and price declines.
- One-Time Items: The quarter included a net benefit of $0.01 per share from one-time items, including a $49 million tax benefit related to the pending sale of the Pharmaceuticals business and a $56 million charge for a settlement regarding Monsanto YieldGard corn litigation.
Guidance, Outlook, and Risks
Outlook: Management expects the U.S. economy to continue weakening through the fourth quarter of 2001. The company forecasts fourth-quarter earnings per share to be roughly similar to the third quarter ($0.12-$0.13 range).
- Positives for Q4: Lower raw material costs, restructuring savings, lower net interest expense, and a reduced share count.
- Negatives for Q4: Lower volumes due to economic deterioration, continued pricing pressure, and lower earnings from the Pharmaceuticals segment (post-sale).
- Risks and Contingencies: The company cites the aftermath of the September 11 events as a factor adding to economic uncertainty and potentially prolonging the downturn. Other risks include foreign currency exchange rates, competitive pressures, and the successful integration of structural changes.
Investor Verification Checklist
- Verify the impact of the $7.8 billion sale of DuPont Pharmaceuticals on the fourth-quarter financial statements, specifically the estimated $4 billion after-tax gain.
- Monitor the severity of the U.S. manufacturing recession and its effect on volume recovery in key segments like Performance Coatings, Nylon, and Polyester.
- Assess the sustainability of raw material cost moderation versus potential price increases in the fourth quarter.
- Review the specific details of the $56 million Monsanto YieldGard settlement reserve to ensure no further liabilities exist.
- Track the progress of the restructuring program and the realization of the estimated $1.4 billion in annualized Six Sigma benefits.